

美中生物医药协会会刊

CABA *Connect*

Chinese-American BioMedical Association Official Newsletter

AUGUST 2009
VOLUME 1, ISSUE 1




🌀 *in this issue* 🌀

- ✧ **President's Message (P.2)**
- ✧ **2009 CABA Annual Conference Reports (P.5 & P.7)**
- ✧ **Job Opportunities (P.15)**

Published by Chinese-American BioMedical Association

CABA
P. O. Box 600241
Newtonville, MA 02460



CABA Connect

A Message from the President

Dear friends,

Chinese-American BioMedical Association (CABA) is delighted to present you the first issue of *CABA Connect*, CABA's official newsletter.

CABA prides itself on our dedication to serving our members and our commitment to promoting public awareness of advancement in the pharmaceutical and biomedical industries, professional interactions in the fields of life sciences, global biomedical innovations and business development. We thrive to serve as a platform for our members to develop and advance their careers in the US bio/pharmaceutical industry as well as a bridge to connect members with the scientific and business resources in China thus to facilitate collaborations between the pharmaceutical and biomedical industries across the continents.

Having successfully organized numerous events including our annual conferences, scientific & investment symposia, and various special forums, we were encouraged to set up additional channels to further enhance the interactions among our members and friends. *CABA Connect* was conceived almost a year ago by a few of our EC members and our esteemed advisor Dr. Roger Tung, CEO and President of Concert Pharmaceuticals. We are hoping this will further help bring together members, scientists, professionals, government officials and business leaders across the continents to achieve their best potentials.

Tremendous respect and gratitude go to the newsletter team of Drs. Qinglin Che (editor-in-chief), Yongzhong Wang (editor), Tony Yuan (editor) and Chaoyang Dai (CABA vice president) for their wonderful, yet extremely challenging work in designing, writing and editing this very first issue of *CABA Connect*! The carefully drafted reports, industry news, job postings, and member highlights will help you better understand our organization, our members including advisors, and the biopharmaceutical society at a glance. We also like to thank our sponsors for their generous support to this newsletter.

I sincerely wish you to find joy in reading this issue of *CABA Connect* and hope to see more volunteers step up and contribute to the future issues. As a non-profit organization, CABA purely relies on your support to move forward. If you wish to contribute in any way, please feel free to let us know.

Zhao-Kui Wan, Ph.D.
President, Chinese-American BioMedical Association

Editor-in-Chief:
Qinglin Che

Editors:
Yongzhong Wang
Tony Yuan

Board of Publications:
Chaoyang Dai, Jun Han,
Yihan Wang, Zhao-Kui Wan,
Junjun Wu, Zhiyong Yang,
Phil Zhang,

Contributing Editors:
Zhihong Chen, Yanni Gou,
Zhiyong Yang, Jingye Zhou

Photographers:
Jun Han and Qinglin Che

CABA CONNECT
Volume 1, Issue 1

Published by:
CABA
P. O. Box 600241
Newtonville, MA 02460 USA
www.cabaweb.org

If you want to subscribe to this
newsletter, please send your
request with updated mailing
address and member
information to
cabacconnect@gmail.com

In This Issue

2. **A message from the President**
4. *CABA China Connection*
Dr. Yanhua Liu, the Vice Minister of MOST, Meets with CABA Members at Harvard
5. *CABA Event Report:*
2009 CABA Annual Conference Report: Featuring Biomedical Innovation and US-China Partnership
10. *CABA Expert Forum*
Strategic Alliance & partnership with China; Generic Drug Development
12. *Special Event Announcement*
Wuhan Hua-Chuang-Hui 2009 Call for Applications
13. *Global Express*
BioMedical News Round-up
15. *Career Center*
Pharmaceutical, Biotech & CRO Job Opportunities
17. *Member Spotlights*
18. *Membership Update*
CABA Board of Directors & Executive Committee Members
21. *Sponsorship Update*

Disclaimer: *CABA Connect* reserves the right to edit, publish, or reject any submission or its contents. Any articles published by *CABA connect* may not be published elsewhere without CABA's consent and permission. Each article represents the author's opinion, not necessarily that of CABA.

CABA China Connection

Dr. Yanhua Liu, the Vice Minister of MOST, Meets with Members and Friends of CABA at Harvard

Reported by Zhiyong Yang, Ph.D.

Dr. Yanhua Liu, Vice Minister of Chinese Ministry of Science and Technology met with members and friends of Chinese-American BioMedical Association (CABA) (<http://www.cabaweb.org>) at Harvard Medical School in the afternoon of November 1, 2008. About 30 distinguished scientists and professionals of Chinese descent from the Boston area attended the event. Dr. Yihan Wang, a member of CABA's Executive Committee, hosted the meeting.

Dr. Liu took the opportunity to give an overview on China's strategies for the development of biotech and pharmaceutical industry. He pointed out that technology, energy and healthcare sectors, in particular the biotech/pharmaceutical industry, will be the next growth engines for the Chinese economy. China is now fully committed to developing innovative products that address major medical needs in the country and the world. He also shared his personal views on how R&D can be more efficiently and effectively conducted in China.

At this meeting, CABA members and friends made many good suggestions on how to improve Chinese biotech/pharmaceutical industry to be better suited for global competition. Dr. Yuan-hua Ding, Director and Head of Asia External Research Network, Pfizer, Inc., gave an introduction on Pfizer's R & D partnership programs in China. Dr. Roger Xie from GSK spoke on small biotech companies with Sirtris as a success story. Dr. Zhao-kui Wan from Wyeth proposed a risk-sharing business model for Chinese companies. He also provided a list of blockbuster drugs which are soon to be off-patent.

Dr. Zhihong Chen from Eisai Research Institute shared valuable insights on how to develop innovative drugs with Chinese brand. Dr. Philip Zhang, a special counsel from Cooley Godward Kronish LLP, touched upon IP issues in Bio/Pharma industry. He also pointed out that the current market situation provides excellent opportunities for China to invest in US biotechnology, healthcare, clean and renewable energy industries. On a similar note, Tony Zhang, Sr. VP of SovereignBank, proposed an idea to set up Chinese BioMed Funds. Shallwei Sun, President of a medical device company in Suzhou, expressed her concerns about the lack of backup fundings for cash-starved biotech startups, particularly when these companies reach critical stages. She opined that Chinese venture capitalists should consider investing more heavily in the biotech/pharmaceutical sector, which has the potential of yielding promising long-term return. Dr. Erxi Wu, a faculty at Harvard Medical School, talked about how scientists in academia can contribute to the growth of biotech/pharmaceutical industry. Dr. Bin Zhou from HMS briefly showed his groundbreaking research work on the identification of a new heart stem cell, which was recently published in Nature and was widely reported in the media. Dr. Zhendong Zhu from Pfizer and Tony Yuan from Novartis shared their views on how to use informatics technologies to facilitate biotech/pharmaceutical R&D.

Minister Liu listened attentively to all of the suggestions and made many very important comments. Open discussions followed the presentations and continued throughout a dinner reception at Royal East (May Flower) Restaurant in Cambridge.

特别报道

医药创新与中美合作: 美中生物医药协会(CABA)2009年会

By 苟燕妮

四月十一日, 复活节的周六, 位于波士顿的美中生物医药协会 (Chinese-American BioMedical Association, 简称 CABA) 2009 年会在麻省理工学院的教工俱乐部里举行。近三百位来自美国和中国生物医药界的同行们参加了这次盛会。从早上八点半到晚上十点半, 组织者和参与者们在这里度过了紧张难忘且卓有成效的一天。

此次年会重在学术研讨和信息交流。上午的主题是: “制药业革新与中美合作”。在外包研究业界 (Outsourcing Research Organization, 简称 CRO) 享有盛誉的六大中国公司的代表们都发表了精彩演说。他们是来自药明康德 (WuXi AppTec) 的副总裁 Richard M Soll 博士, 凯美隆 (Chemizon) 计算科学与信息部总监倪海洪博士, ChemPartner 的高级副总裁徐亚君博士, 保诺科技 (北京) 有限公司 (BioDuro) 生物、化学分析资深总监邓天敬博士, 上海美迪西生物医药有限公司 (Medicilon) 首席执行官张锦涛博士以及桑迪亚医药技术公司联友制药技术公司 (Sundia) 执行副总经理施雄伟博士。他们介绍了公司在最近几年里呈几何级数增长的优势, 公司的服务方向和能力, 言语中带着创业者们独有的自豪感。他们普遍认为中国生物制药业的发展占尽“天时、地利、人和”, 挑战和机遇并存, 从现在到今后的几年, 前景看好, 这或许会给受美国经济大危机冲击的美国制药行业的从业者带来些许的亮色和希望。美国生物制药外包界的 GenScript 总裁王鲁泉博士以及服务咨询公司 Aptuit Consulting 总裁 William Kerns 对本公司新药研发的服务项目以及与合作前景都做了很有说服力的分享。在中间休息以及午餐时间, 与会者们参观了各家公司的展台和就业问询。大家相互认识, 交流信息, 各取所需, 气氛非常融洽。

下午的会议有两个主题, 一是“生物医药业科学技术的最新进展”, 二是“法律和专利保护, 规则和风险投资”。美国的几大生物制药公司重量级人物给了非常全面和深刻的演讲。他们是 Novartis 全球传染病研究领域副总裁 Steve Projan 博士, Schering-Plough 波士顿剑桥研发中心总负责人副总裁 John Piwinski 博士, Ariad 的高级副总裁科学执行官 Tim Clackson 博士, 以及 Genzyme 生物外科高级总

监 Gary du Moulin 博士。这些演讲技术含量极高, 从寻找活性体到合成成品药, 从大制药公司在中国的研发现状到在北京建大楼以及设计实验室, 从研发机构的转型到寻找新药的成功与失败经验, 涵盖面很广。法律、专利、规章和投资也是热门话题。

Cooley Godward Kronish 律师事务所的 John Hession 和张引博士就大家所关心的中国专利保护和在医药生物方面的运用作了比较通俗易懂的阐述。投资公司 SV Life Science Ventures 的李浩贤先生对有意创业的有识之士提供了怎样成功地获得投资者的赞助的诀窍。在开放式提问之后, CABA 会长吴俊军作了总结性发言。他对讲员的精彩演讲以及年会的赞助单位和会员们深表感谢。同时他还简单介绍了协会发展的历史和现状以及下一任会长万昭奎博士和由二十名骨干组成的新一届 CABA 领导团队。

在鸡尾酒会之后, 来自 Wyeth Research 的副总裁和化学研究部总负责人 Tarek Mansour 博士作了题为“科学创新与合作”的重要讲话。Tarek 幽默地表示他的讲话不容易, 因为需要和晚餐来竞争。事实上“听君一席话, 胜读十年书”, 与会者们听得有滋有味。Tarek 既引经据典又深入浅出, 他把化学中寻找新药领域的创新经验和合作意识融汇贯通, 举了

三个例子涵盖从研发到临床再到被美国医药食品部门 (FDA) 批准的新药, 令人耳目一新。他的精彩演说赢得了雷鸣般的掌声。接着, CABA 的创始人之一、在 Ariad 任副总监的王义汉博士再次升华了此次年会的主题: 在这个全球一体化的世界里, 我们需要携手为人类科学技术的发展尽我们的一份力量, 希望大家把创新意识融入 美国、中国以及世界各国的生物医药行业中。在轻松愉快的氛围里与会者们享用了教工俱乐部的简便可口的晚餐, 虽然有非亚裔的朋友开玩笑说他期待的是一顿中国饭菜。

整个会议既严肃也轻松, 起到了拓宽视野、学习新知、广识同行的作用。讲员和听众都公认这次年会是一个高质量、高水准、高素质的年会, 对组织者们的组织管理的能力和细节安排的匠心大加赞赏。会议结束之后, 组织者收到了来自四面八方的鼓励和赞誉。Wyeth Research 的副总裁和化学研究部总负责人 Tarek Mansour 博士说: “我很荣幸能够参加 CABA 的年会, 在这里我听到了很多的参与者们对会议成功的赞扬声。我能感觉到这是一个温暖而相互支持的团队, 你们应该为会议的成功而骄傲, 为你们协会所倡导的创新和合作而自豪”。药明康德 (WuXi AppTec) 的 Richard M Soll 博士表示这次年会非常成功, 有助于同行交流和合作。GenScript 王鲁泉博士表示这是他第一次参加 CABA 的年会, 他对组织者们的组织能力和 服务精神大加赞许, 希望进一步的合作。凯美隆 (Chemizon) 倪海洪博士, ChemPartner 的徐亚君博士以及保诺科技 (北京) 有限公司 (BioDuro) 邓天敬博士以及桑迪亚医药技术公司联友制药技术公司 (Sundia) 的施雄伟博士, 上海美迪西生物医药有限公司 (Medicilon) 张锦涛博士等都表达了相同的心声。

美中生物医药协会 (CABA) 成立于 2007 年, 是一个在波士顿地区生物医药行业较为年轻的非赢利性组织。它的宗旨是交流科学信息, 为中美同行提供求职和交流的平台。他们崇尚“真诚, 信实, 负责, 可靠”的服务精神, 力主“专业化, 科学化”的职业路线。协会自成立以来非常活跃, 除了两次年会外还举办了一些倍受欢迎的专业讲座和活动。协会发展迅速, 现有成员 三百多人。今年六月十三和二十日, CABA 在麻省理工学院举办了题为“临床试验和药物规范 (Clinical Trials & Regulatory Affairs)”的讲座。目前他们正为今年十月份在武汉举办的“2009 武汉华创会”紧锣密鼓地开展组织工作。如对协会举办的活动有兴趣, 请查看网址 www.cabaweb.org。如果您也是生物制药行业的同行, 欢迎加入 CABA 这个温暖而充满活力和生机的年轻组织! 如果您参加了这次年会, 希望您也度过了颇有收获的一天。。。下次见!

会议组织者和部分与会专家合影



CABA Event Report

CABA 2009 Annual Conference Report: Featuring Biomedical Innovation and US-China Partnership

Reported By William Yongzhong Wang, Ph.D.

As the VP and Head of Chemical Sciences of Wyeth Research and an over 30-year veteran in academia and industry, Dr. Tarek Monsour is no stranger to annual conferences of professional organizations. However, he was greatly impressed by the 2009 annual conference of a relatively young organization, Chinese-American BioMedical Association (CABA). One day after delivering the keynote speech at the conference, he wrote, "I sensed a strong sense of warmth and collaboration/support by the participants. This is a great thing accredited to the founders and the Chairs and Committees to promote themes in science and technology. You should be very proud of this achievement and accomplishment. I heard so many positive comments from participants and speakers about the day so again this is a strong testimony for your vision and leadership as an organization".

Dr. Monsour's impression was indeed shared by many prominent speakers and seasoned biotech professionals who attended the one-day conference held at the MIT faculty club on Saturday, April 11, 2009. Dr. Tim Clackson, the Senior Vice President and Chief Scientific Officer at Ariad Pharmaceuticals Inc presented the innovations made by Ariad at the conference and commented afterwards, "it was a really great conference and you and your colleagues are to be congratulated. I look forward to my continued involvement with CABA."

With an audience of around 300 from United States and

China, the conference drew its energy from the concentrated science, education, and medicine community of "Genetown" Cambridge and its adjacent areas, as well as a prosperous pharmaceutical industry in China. Its success was a tribute to strong support from many local and international pharmaceutical and biomedical companies (for a complete list of conference sponsors, please visit www.cabaweb.org).

The theme of the conference was "biomedical innovations and US-China partnership". It featured 4 sessions and 16 high profile speakers including senior executives from top Chinese CRO companies such as WuXi AppTec, ChemPartner, Chemizon, BioDuro, Medicilon, Sundia, and GenScript; major pharmaceutical companies such as Wyeth, Novatis, Genzyme, and Schering-Plough, as well as seasoned VC and IP lawyers (for a complete program and a list of speakers, please visit www.cabaweb.org).

The morning sessions were hosted by Drs. Chaoyang Dai and Wendy Zhang. Senior executives from the Chinese companies excited the audience with the rapid development, emerging opportunities, and challenges of the biotech industry in China and its significant impact on the global market. The two afternoon sessions, chaired by Drs. Zhiyong Yang, Sue Ma, Phil Zhang and Yongzhong Wang, focused on latest innovations made in the discovery and development of new therapeutic regimens, as well as the critical legal/IP/investment issues involved in the process.

Dr. Tarek Mansour delivered the keynote speech in the evening session, hosted by Dr. Zhao-Kui Wan of Wyeth. Reflecting the theme of the conference, Dr. Mansour enlightened the audience how to fundamentally define and measure true innovations with case studies including one FDA approved drug, one drug in advanced stage of clinical trial, and one drug candidate in early development stage as well some innovative methodologies derived from the drug discovery researches. As Dr. Yihan Wang, Associate Director at Ariad and one of the founders of CABA, put in a perfect way in his closing remarks - now it is time for us to think about how to bring real innovations to biomedical industry in US, China and all over the world. Especially for the young biomedical industry in China, which historically has strongly relied on outsourcing business, innovations will eventually determine its status in the rapidly changing global market.

In addition to the speeches and discussions, a vendor show was held throughout the day, which drew constant attentions from the attendees and extremely positive responses from both the vendors and the attendees. The organizers and the participating sponsors also put together a job fair at lunch time to benefit those who are seeking career opportunities. That proved to be another bright spot at the conference given the tough pictures of the current economy and job market.

Many attendees including Dr. Steven Projan, the Global Head of Infectious Diseases at the Novartis Institutes for BioMedical Research and Dr. John Piwinski, Group VP and Site Head of Schering-Plough, Cambridge (who both also presented at the conference) were impressed by the turnout on the Easter weekend and the high quality of the conference.

Dr. Jia Huang of Serica Technologies wrote afterwards, “the event was very successful! The organization and the

quality of the speakers were of the highest level among all the similar events I've been to.”

Dr. Larry Wang, President of GenScript mentioned, “This is my first CABA meeting, and I am very impressed by the smooth organization and service attitude of the CABA team.”

Dr. Richard Soll, VP of Medicinal Chemistry of WuXi AppTec also presented and later wrote, “it was a great experience for me to be part of the CABA conference and I enjoyed the event very much. Excellent forum for current awareness and networking.”

Charles Huang, VP of Business Development of Sundia commented, “It is a great success! I would like to congratulate you for this significant event, and admire your effort and contributions to the drug discovery community, and the exchange of the US/China pharma/biotech industry.”

For the organizers, the conference did not end with merely patting on each other's backs for a job well done. CABA's leadership team, led by President Dr. Junjun Wu and the newly elected President Dr. Zhao-Kui Wan of Wyeth, has set their eyes and minds on the future. Riding on the success of the annual conference, Dr. Wu announced in his remark that two events will be held in the near future: “CABA Workshop on Clinical Trials & Regulatory Affairs” with two sessions on June 13, and 30 at Harvard Medical School; 2009 Wuhan Huachuanghui Bioforum co-organized by CABA in October in central China city Wuhan. For those who are interested in biomedical research, it will be definitely beneficial to regularly check out CABA's website: www.cabaweb.org to see what's happening next. From the other end, CABA likes to say: “Stay Tuned!”

ALL-CABPA



Alliance of Chinese-American Biotechnology and Pharmaceutical Associations

全美华人生物医药协会联盟

News Flash

All-CABPA Has Been Formed

The Chinese American organizations in the biotechnology and pharmaceutical field have formed the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA). The current members include: the Chinese Biopharmaceutical Association (CBA), headquartered in Washington DC; the Chinese-American Biopharmaceutical Society (CABS), headquartered in San Francisco, CA; the Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), headquartered in San Diego, CA; and the Chinese-American Biomedical Association (CABA), headquartered in Boston, MA.



Trends in Bio/Pharmaceutical Industry (TBI)

Trends in Bio/Pharmaceutical Industry (TBI) is the official journal of the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA).

TBI is a scientific journal focused on the latest discoveries, innovations, development and trends in the various fields of life sciences, especially in research institutes and pharmaceutical and biotechnology industry. The targeted readers of TBI are researchers, scientists, entrepreneurs and senior managers. TBI is published quarterly both online and in hard copies. For previous issues, please check TBIWEB. Samples of hard copies are also available by request.

CABA Expert Forum**Strategic Alliance & Partnership with China and Generic Drug Development**

Reported By Zhihong Chen, Ph.D.

Pharmaceutical / biotech industry is facing serious challenges in bringing new drugs into the market due to low rate of success, more competitions, looming patent expirations, increasing regulatory scrutiny, increasing cost, and pressure to lower prices. The current global economic downturn has certainly made these challenges more evident. What are the solutions? This is a topic that interested many professionals in the pharmaceutical industry today.

On May 15, Chinese-American BioMedical Association (CABA) held a special Expert Forum on the new trend for drug innovations featuring two top experts in pharmaceutical /biotech industry, Dr. Jing-Shan (Jennifer) Hu, Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan), Merck & Co., Inc. and Dr. Jun Han, Global R&D Project Manager of Teva Pharmaceutical Inc.

In her presentation titled “New Trend for Success in Biotech/ Pharma Innovation: Strategic Alliance and Partnership with China”, Dr. Hu pointed out that organizations such as small, big biotech/pharmaceutical companies and academic institutions have different strengths and weaknesses and are facing different challenges. To overcome the challenges, biotech/pharmaceutical companies and academic organizations chose to form strategic partnerships with each other to build their competitive edge

in biomedical and pharmaceutical innovations. China in particular has recently started to play more and more important roles in this area. Many global pharmaceutical companies have built R & D centers in China. At the same time, more and more Chinese biotech companies and research labs have been established by returnees with significant global experience and reputation. Not surprisingly, one of the strategies shared by the global companies and the recently established Chinese companies is to build partnership with biotech and academic organizations in China to utilize their strengths.

The second half of this event was held in a more casual way. After briefly induced the basic ideas on how to initiate and advance generic drug development, Dr. Jun Han conducted an interactive Q&A section with his audience. Dr. Han made a side-to-side comparison of new drug discovery and generic drug development



Dr. Jing-Shan Hu (first row, second from left) and Dr. Jun Han (standing, first from left) along with forum organizers and some attendees.

based on his extensive R&D and portfolio management experience in both areas.

The presentations and discussions by both speakers received positive feedbacks and enthusiastic responses from the audience, who are more than forty pharmaceutical and biomedical researchers,

entrepreneurs and other health care professionals from industry and academic institutions. The engaging style, knowledge of the industry, ability to connect with the audience from Dr Hu and Dr Han captured and held the audience's interest from beginning to end.

Biosketch of SPEAKERS



Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and

development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc., Dr. Hu spent over three years with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology Pharmaconomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program.

Dr. Hu got her B.S. degree in Biochemistry from Peking University; Ph.D. from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association - West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 16 years of research, management, & business development experience in biotech and pharmaceutical industry in the US.



Dr. Jun Han is currently the Global R&D Project Manager for Barr Pharmaceutical Inc. He is responsible for managing and coordinating global R&D projects from identification, initiation to submission. Prior to joining Barr in 2007, Dr. Han spent over three years with Novartis Institute for BioMedical Research at Cambridge as

Research Fellow, Senior Fellow and Lab Head of the Chemical and Pharmaceutical Profiling group. Prior to that, He spent three years in the department of Pharmaceutics and New Technologies as a Senior Scientist at Abbott Laboratories and three years in the Preformulation group at Wyeth Pharmaceuticals. Dr. Han received his Ph.D. in Pharmaceutics from University of Minnesota - Twin Cities and a B.A. in Pharmacy from the Second Military Medical University in Shanghai, China. He also received post-doctoral training at Sanofi-Aventis in Collegeville, PA. Dr. Han authored 13 papers in peer reviewed journals and given more than 40 presentations in international conferences. Dr. Han is the recipient of McBride Award in Thermal Analysis (MTAF), Procter & Gamble Award in Drug Delivery and Pharmaceutical Technology (AAPS), Outstanding Graduate Research Award in Pharmaceutical Technologies (AAPS), Pharmaceutical Analytical Research & Development Innovation Award (Abbott), Pharmaceutical Analytical Research & Development Teamwork Award (Abbott), and Perkin-Elmer Award (NATAS). Dr. Han is an executive committee member for the AAPS Preformulation focus group and a member of AAPS Drug Discovery and Delivery Interface (D3I) Task Force. He was elected as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association - New England (SAPA-NE) and was the Founding President of Chinese-American BioMedical Association (CABA). Dr. Han also participated in the initiation and founding of the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations.

CABA Special Event Announcement

Hot! Wuhan Hua-chuang-hui 2009 (华创会) Call for Applications

Wuhan Hua-chuang-hui 2009 will be held from Oct 15~17. The application is re-open for US Bio/Pharma delegation. Thanks for your interest in joining the delegation.

CABA is working with other Chinese-American professional organizations including CBA based in Washington DC), CABS headquartered in San Francisco, CA), SABPA headquartered in San Diego, CA) and others to form a delegation to attend the 9th Hua-Chuang-Hui in Wuhan (Business and Investment conference of Overseas Chinese Engineers and Scholars).

Hua-Chuang-Hui (华创会) focuses on business opportunities in high-tech fields including Biotech/Pharma. To learn more details about Hua-Chuang-Hui, please go to www.hch.org.cn.

Location: Wuhan (武汉新世界大酒店, 武汉科技会展中心)

Time: Oct 15-17, 2009

Optional: CABA is organizing a delegation to visit Shanghai Zhangjiang High Tech Park and several drug discovery CROs,



CABA co-organized International Bioforum at Hua-chuang-hui 2008 in Wuhan

Suzhou Industrial Park, Wuxi B-Park. Please contact Dr. Junjun Wu (Junjun_wu_1@yahoo.com) if you are interested in joining this group. The delegation is also invited to participate in a few related events in other cities around the same time.

Who can apply: Scientists who are seeking opportunities to turn your business ideas into reality in China. CABA are responsible for collecting business proposals in the areas of biotechnology /pharmaceuticals / medical devices, and forming the delegation. The local meeting expenses will be covered by the meeting organizers (国务院侨办, 湖北省政府, 武汉市政府, 湖北省药监局, 武汉国家生物产业基地). If you are interested, please fill in the attached form in Chinese to include a short biosketch (1 paragraph) and a brief summary of your business proposal (1/2 - 1 page). To find out more about the requirements and the format of the proposal, please visit Hua-Chuang-Hui website. Please email the filled form to Drs. Junjun Wu (Junjun_wu_1@yahoo.com) or Yihan Wang (yihanw@yahoo.com). CABA and Hua-Chuang-Hui organizers will work together to evaluate the proposals. Qualified applicants will be selected as members of the delegation.

CABA Global Express**BioMedical News Round-Up**

Compiled by Jingye Zhou, Ph.D.

**CONCERT IN POTENTIAL \$1B GSK DEAL**

GlaxoSmithKline and Concert Pharmaceuticals announced that they will collaborate to develop and commercialize deuterium-containing medicines. The deal includes three of Concert's research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert's pipeline. Concert will also provide GSK with deuterium-modified versions of three GSK pipeline compounds for GSK to develop. Under the terms of the agreement, Concert has the potential to receive in excess of \$1 billion in total milestone and upfront payments from GSK spread across all programs.

For each Concert pipeline program, Concert will have responsibility for research and development activities through completion of pre-agreed clinical trials. After the completion of such clinical trials for each program, or earlier if it chooses, GSK may elect to obtain an exclusive, worldwide license to product candidates within the program. At such time, GSK will assume responsibility for development and commercialization. Concert will retain full rights to further develop and commercialize its product candidates in any program GSK chooses not to license.

"We are pleased to collaborate with GSK and to advance innovative small molecule drug candidates using our deuterium chemistry approach," said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. "This collaboration is a major step forward in our strategy to advance a broad pipeline of novel deuterium-modified therapeutics."



Dr. Tung co-founded the Company in April 2006 based on research he carried out as an independent scientist. Prior to Concert, Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals Inc., where he was a founding scientist, Merck, Sharp & Dohme Research Laboratories, and The Squibb Institute for Medicinal Chemistry. At Vertex, Dr. Tung was most recently Vice President of Drug Discovery and led their drug discovery programs at its San Diego site. He co-invented and headed discovery of Vertex's two commercial HIV protease inhibitor products, Lexiva and Agenerase. He also headed development of Agenerase, in collaboration with Glaxo, through FDA and EMEA approval. Dr. Tung has overseen the discovery of 14 new chemical entities which have been studied in the clinic. He has numerous publications and has been granted 40 U.S. patents. Dr. Tung received his Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich.

Dr. Tung is no stranger to CABA's members, he was invited to deliver the keynote speech at CABA's 2008 Technology, Investment/Entrepreneurship Symposium, when he shared with us the vision behind Concert and introduced his company's unique approach and platform that substantially reduces the risks associated with current drug development and rapidly creates first and best-in-class new medicines. He is currently on the advisory board of CABA. (-QC)

U.S. ORDERS SWINE-FLU VACCINE

The federal government is committing more than \$800 million to buy more of the two key ingredients to make the H1N1 swine flu vaccine, according to the Department of Health and Human Services. Swiss company Novartis (NYSE: NVS), which is building a vaccine manufacturing facility in Holly Springs, received an order for \$346 million for antigen and \$343.8 million for adjuvant. London-based GlaxoSmithKline (NYSE: GSK) received an order for \$71.4 million of adjuvant. In addition, Sanofi Pasteur received a \$61.4 million order for antigen, and MedImmune won a \$61 million order for its nasal flu spray.

SINOVAC RECEIVES CHINA'S FIRST INFLUENZA A (H1N1) VACCINE ORDER

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced that the Company received the first order in China to supply its influenza A (H1N1) vaccine to the Beijing government. The initial order consists of 4 million doses and is expected to be delivered by the end of September. This order will be administered to 2 million people in the high risk group. Additional orders are expected beginning in October and, in total, Sinovac expects to supply approximately 10 million doses to the Beijing government. The 10 million doses will be administered to 5 million people in Beijing. (June 22nd, 2009)

SKYSTAR BIO-PHARMACEUTICALS BEGINS TRADING ON NASDAQ

Skystar Bio-Pharmaceutical Co., Ltd., a leading China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives, announced that its common stock will begin trading on the NASDAQ Capital Market under the symbol SKBI, effective at the open of trading day, June 26, 2009.

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, microorganisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China.

HONG KONG LAYS FIRM FOUNDATION IN BIO AND NANOTECH

Hong Kong had laid a firm foundation for developing biotechnology and nanotechnology in the years to come and the Government would continue its investments in both fostering stronger research and nurturing a thriving industry, Assistant Commissioner for Innovation and Technology, Mr Nicholas Chan said.

The Innovation and Technology Fund was established in 1999 with an allocation of \$5 billion, to support applied R&D projects that would enhance Hong Kong's international competitiveness. To date, the fund has supported about 1,400 projects with a total investment of about \$4 billion, biotech and nanotech account for more than 12% of the funding. (June 22nd, 2009)

CHINA CHEMSPEC IPO RAISES \$72.2 MILLION

Chinese chemical company Chemspec International Ltd (CPC.N) raised \$72.7 million in its initial public offering after pricing its U.S. shares at \$9 each, at the top end of its estimated price range, one of the deal's underwriters said. Chemspec, a Shanghai-based maker of fluorinated

specialty chemicals, had estimated in a filing earlier in June that its American Depository Receipts (ADRs) would price between \$7 and \$9. (July 12th, 2009)

SHANGHAI CHEMPARTNER AND SKK ANNOUNCE STRATEGIC ALLIANCE

Shanghai ChemPartner Co., Ltd., (ChemPartner) a group company of ShangPharma, and Sanwa Kagaku Kenkyusho Co. Ltd. (SKK), a pharmaceutical company headquartered in Nagoya, Japan, today announced that they have entered into a strategic alliance. The partnership was formed as a key element of a strategic initiative for SKK to target the Asian market, in step with SKK's new medium-long term business plan and expanding presence in diabetic research and will help SKK to achieve its drug discovery goals. Commenting on this alliance, Michael Hui, CEO of ChemPartner said, "We are delighted to be entering this strategic alliance with SKK. We are proud and honoured that SKK have selected ChemPartner to be one of their partners and we look forward to building a long and successful relationship between our two companies in the future." The business terms and details of this project were not disclosed. (April 20th, 2009)

WUXI PHARMATECH NAMED CHINA'S TOP 10 OUTSOURCING COMPANIES

WuXi PharmaTech (药明康德) was named one of the Top Ten Leading Outsourcing Enterprises in China, a list selected by China's Ministry of Commerce. The ministry announced the composition of the list at the recent Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing. WuXi PharmaTech, a highly visible China CRO with additional operations in the US, is the only representative of the healthcare sector on the list. (July 6th, 2009)

SUNDIA IN TOP 100 FAST-GROWTH CRO IN CHINA

Sundia MediTech (桑迪亚) was named as a Top 100 Fast-growth Outsourcing Service Provider. This selection was jointly sponsored by China Council for International Investment Promotion (CCIIP) and three global leading market researchers, TPI, IDC and Gartner. This ranking covers outsourcing services in IT, pharmaceutical, biotech, and all industrial fields.

As a leading pharmaceutical R&D CRO company, Sundia is consistently focused on providing high quality CRO services to pharmaceutical and biotech company clients worldwide. Since its founding in 2004, the company's CRO service business has been growing at a high rate. (July 20th, 2009)



CABA Career Center

Pharmaceutical, Biotech & CRO Job Opportunities

Compiled By Tony Yuan



The Formulation Sciences Department at Randstad is seeking a Pharmaceutical Scientist to be responsible for oral formulation and process development of small-molecule therapeutics. Specific responsibilities include supervising a staff of scientists and engineers, managing the cross-functional development and outsourcing operations, allocating department resources, managing the outsourcing budget, and reviewing regulatory documents. The candidate will participate in multidisciplinary CMC teams.

DUTIES & RESPONSIBILITIES

- Leads Formulation Science group, which is responsible for oral-dosage formulation development and clinical trial material manufacturing
- Ensures consistent application of sound scientific and engineering principles and industry best practices
- Works closely with other drug product development functions (esp. Analytical Development) to ensure the resources are allocated to meet project goals
- Works closely with Process Chemistry and Supply Operations to ensure that drug substance and CTM supply/demand plans are established and executed
- Works closely with Divisional Business Operations functions to ensure proper execution of budgeting and contracting processes;
- Manages outsourcing budget
- Monitors and evaluates vendor performance with input from relevant CMC functions; coordinates and oversees corrective development plans and remediation effort
- Influences CMC regulatory strategy and reviews regulatory documents

- Participate on multidisciplinary CMC and project teams

Preferred Qualifications:

- Ph.D. in Pharmaceutics, Chemical Engineering, or related discipline
- At minimum, 8 years of solid-dosage formulation development experience
- At minimum, 3 years of supervisory experience
- Proven record of successful people and project leadership the ability to develop collaborations across functions and teams; to negotiate; and influence a diverse set of stakeholders
- Knowledge of FDA and ICH guidelines and IND/CTD submission processes
- Development of oncology therapeutics
- Experience with outsourcing management
- Experience with preformulation is a plus
- Experience with NDA submission process is a plus

Basic Qualifications:

- Ph.D. in Pharmaceutics, Chemical Engineering, or related discipline
- At minimum, 8 years of solid-dosage formulation development experience
- At minimum, 3 years of supervisory experience

For more information regarding to this position and others, please contact:
 Randstad US
 1430 Massachusetts Avenue
 Cambridge, MA 02138
 T 617.354.7215
 F 617.354.7476
 yushen.chang@us.randstad.com
 website: <http://www.randstad.com>



WuXi AppTec welcomes overseas chemists and formulators join us. We offer you a highly competitive compensation and full benefits package along with an exciting world-class work environment. For more information, please visit our website: <http://www.wuxiapptec.com/>. For prompt consideration, please send your CV to: hr@wuxiapptec.com.

Philadelphia Opportunities

Research Assistant I - Molecular Biology
 Research Assistant I - Analytical Biochemistry
 Reserach Assistant I - Virology

Atlanta Opportunities

Sterility Manager

Shanghai Opportunities

Vice President of Medicinal Chemistry
 Executive Director/Senior Director/Director of Medicinal Chemistry
 Project Team Leader of Medicinal Chemistry
 Principal Scientist/Senior Scientist of Medicinal Chemistry
 Executive Director/Senior Director/Director of Formulation development
 Senior Director/Director of Pre-formulation development
 Executive Director/Senior Director/Director of Process Development
 Principal Scientist of Analytical Development
 Senior Director/Director of Analytical Development
 Principal Scientist of Process Development
 Senior Director/Director/Associate Director, Enzymology
 Senior Director/Director/Associate Director, Receptor Pharmacology

Senior Research Fellow/Research Fellow/Associate Research Fellow, In Vivo Biology (multiple positions)
In Vivo Drug Discovery Scientists for Pain

Suzhou Opportunities

Study Director of Toxicology
Veterinarian Ophthalmologist
Attending Veterinarian
Clinical Pathologist
Pathologist
Biologist III/Biocompatibility
Biologist III/Trainer
Jinshan Opportunities
Senior Director/Director of QC



Sundia offers a competitive compensation and benefits package, and an exciting atmosphere conducive to career growth. Interested individuals shall send a cover letter indicating the position applied for and the skills matched, along with a resume including references and publications.

E-mail to hr@sundia.com with your resume or inquiries about openings. Or contact us by the mailing address:

Human Resources
Sundia MediTech Company Ltd.,
Building 8, 388 Jialilue Road,
Zhangjiang High-Tech Park,
Shanghai, China 201203 For more information, please visit our website:
<http://www.sundia.com/>

Group leader/Senior biologist (Job Code: SMC-C05)

Job Description: The position leads a group of in vitro biologists, working on assay development, protein expression/purification or conduct HTS screening and exploratory activities.

Qualifications: PhD with 2 years or MS with 5 years experience in molecular biology and biochemistry or related field.

Project Manager (Job Code: SMC-C04)
Qualifications:

-Ph.D. in Organic Chemistry or Medicinal Chemistry with several years of independent research experience.

-Experience in project management and lab management is required.

-Must have published papers or patents in organic chemistry or related fields.

-Must be able to communicate in English for daily work.

-Honest, responsible, self-motivated, innovative, and team-spirited individual.



Answers That Matter.

Lilly Singapore Centre for Drug Discovery

The senior drug hunter leads a team of chemists to deliver high quality leads or drug candidates employing the highest scientific standards.

Responsibilities: The scientist in this position will focus efforts on driving the medicinal chemistry strategy for assigned projects coming from Lilly Singapore Centre for Drug Discovery's (LSCDD) research activities, primarily through a regional partner network model, coordinating chemistry outsourcing activities and/or external collaborations. He/she plays a strategic and operational role in interactions with CROs, academic research groups, alliance partners and professional societies in the region. He/she will as needed, collaborate and communicate effectively across Lilly Global Chemistry Resources as well as other cross functional areas such as biology, pharmacokinetics, toxicology, biopharmaceutical and process chemistry. The scientist in this position is also responsible to work with Patent attorneys to drive patent strategies and ensure an appropriate intellectual protection strategy for assigned projects. He/she will report to Chief Scientific Officer of LSCDD.

Requirements: A PhD in chemistry with five or more years of medicinal chemistry experience in pharmaceutical/biotech industry. The candidate should be familiar with the whole drug discovery process including lead generation, lead optimization, in vivo pharmacology, biopharmaceutical science, process development and preclinical safety assessment. He/she must demonstrate a proven track record as a scientific leader within the pharmaceutical industry, which requires critical decision making on successful project transitions and terminations, effective resource utilization and publications/presentations/ patents. Excellence in oral and written communication skills with internal and external collaborators is a key requirement given the model through which LSCDD operates.

Interested candidates are invited to send CV to suresh@globeitstaffing.com



S&T Global, Inc, located in Woburn, MA, is an emerging company working on drug discovery and small-scale intermediates production for pharmaceutical companies. The synthetic organic chemistry team currently has opportunities for **organic chemists** who will practice synthetic organic chemistry and work on challenging projects. Qualified candidates should have an MS or Ph.D. degree in organic chemistry, with 2-3 years experience in organic synthesis. For more information please contact john and send your resume by email to john@stglobalz.com. For more information, please visit our website: <http://www.stglobalinc.com/>.

FREE registration to Fall ACS National Meeting in Washington, DC and use of ACS Career Fair are available for unemployed ACS members. Unemployed members can tap into a host of valuable benefits and services that help them get back in the workforce. And, members in good standing may qualify for an unemployed member dues waiver, allowing them to renew their memberships and keep their member benefits at no cost. Contact ACS at service@acs.org, 800-333-9511 or 614-447-3671 or visit www.acs.org for details.





CABA Member Spotlights



-  CABA welcomes six new advisory board members: Dr. Roger Tung, CEO and President, Concert Pharmaceuticals, Lexington, MA; Dr. Steve Projan, Vice President, Global Head of Infectious Diseases, Novartis Institute of BioMedical Research, Cambridge, MA; Dr. John Piwinski, Group VP and Site Head, Schering-Plough Research Institute, Cambridge, MA; Dr. Tarek Mansour, VP and Head of Chemical Sciences, Wyeth Research Institute, Wyeth Pharmaceuticals; Dr. Liming Shao, Senior Director, Medicinal Chemistry, Sepracor Inc., Marlborough, MA and Dr. Pierre Frederic Dodion, Senior VP and CMO, ARIAD Pharmaceuticals, Cambridge, MA.
-  2008 CABA Outstanding Contribution Awards were given to Fred Gilman, partner of Lynch, DeSimone & Nylen, LLP, Dr. Herong Yang, Chief Architect of Open Channel Solutions, Boston, MA, and Dr. Yihan Wang, Associate Director of ARIAD Pharmaceuticals, Cambridge, MA, for their significant and lasting contributions to the organization. Fred is CABA's legal counsel who helped set up the organization in 2007 and provided legal consultation to CABA's operation; Yihan is a co-founder and treasurer of CABA; Herong is a CABA executive committee member and webmaster.
-  Dr. Zhao-Kui Wan, principal research scientist at Wyeth Research Institute, Cambridge, MA, was awarded "Young Industrial Investigator Award" by the American Chemical Society Division of Organic Chemistry and Division of Medicinal Chemistry at fall 2008 ACS annual meeting at Philadelphia. Zhao-Kui is current president of CABA.
-  Dr. Roger Xie, formerly with Sirtris Pharmaceuticals as associate director, has joined Beijing PharmaScience(BPS) as chief executive officer. BPS is a service company providing optimal chemistry outsourcing solutions from discovery and medicinal chemistry to large scale manufacturing. Roger is currently a CABA executive committee member.
-  Dr. Jinbo Lee, formerly with Ensemble Discovery as chemistry head, has founded Sage Partner International and serves as the president. Sage Partner provides consulting service to pharmaceutical and biotech companies on drug discovery and contract research. Jinbo is currently a CABA executive committee member.
-  Dr. Xiaowei Jin joined Shanghai Medicilon as the VP of Biology. Medicilon is an integrated life science R&D service company offering biology, chemistry, and preclinical research services to worldwide pharmaceuticals and biotech companies. Xiaowei is an active CABA member.
-  Dr. Weiyi (Wendy) Zhang left EMD Serono, Rockland, MA and joined Sundia MediTech, Shanghai, as senior director of Business development. Wendy is a CABA executive committee member.
-  Fred Gilman, partner of *Lynch, DeSimone & Nylen, LLP*, was named "Pro Bono Superstar" by Lawyers Clearing House, Boston Bar Association for his outstanding legal service to several nonprofit organizations including as legal counsel of CABA.

Membership Update**2009-2010 CABA Board of Directors, Executive Committee Members****President**

Zhao-Kui Wan, Ph. D.
Principal Research Scientist, Wyeth
Research, Cambridge, MA

Vice President

Chaoyang Dai, Ph. D.
Principal Scientist, Schering-Plough
Research Institute, Cambridge, MA

Zhiyong Yang, Ph. D.
Principal Research Scientist, Wyeth
Research, Cambridge, MA

Executive Committee Members

Qinglin Che, Ph. D.
Research Scientist, Synta
Pharmaceuticals, Inc., Lexington, MA

Zhihong Chen, Ph. D.
Sr. Research Investigator, Eisai
Research Institute, Andover, MA

Kevin Fang, Ph. D.
Senior Director, Discovery & Early
Clinical Research, Sepracor Inc.,
Marlborough, MA

Jinbo Lee, Ph.D.
President, Sage Partner
International, Boston, MA

Shiwen Lin, Ph. D.

Associate Director, Antigenics, Inc.
Lexington, MA

Fushuang Liu
Vice President, Wuxi Howfond
Biopharma Co., Ltd., Wuxi, China

Sue Ma, M. D.
Investigator, Novartis Institute of
BioMedical Research, Cambridge, MA

Haihong Ni, Ph. D.
Director of Computational Science,
Chemizon, Beijing, China

Lixin Shen, Ph. D.
President and CEO, Wuxi Howfond
Biopharma Co., Ltd., Wuxi, China

Shallwei Sun
President, Callisyn Pharmaceuticals,
Inc, Boston, MA

Ze Tian, Ph. D.
Investigator, Children's Hospital
Boston/Harvard Medical School,
Boston, MA

Yihan Wang, Ph. D.
Associate Director/Chemistry, ARIAD
Pharmaceuticals, Inc., Cambridge, MA

Yongzhong Wang, Ph. D.

Staff Scientist, Genzyme
Biosurgery/MTS, Cambridge, MA

Zhigang Wang, Ph. D.
Sr. Principal Scientist, Pfizer Research
Technology Center, Cambridge, MA

Erxi Wu, Ph. D.
Assistant Professor, Department of
Pharmaceutical Sciences, North
Dakota State University, Fargo, ND

Roger Xie, Ph. D.
CEO, Beijing PharmaScience,
Beijing, China

Herong Yang, Ph. D.
Chief Architect, Open Channel
Solutions, Boston, MA

Yongwen(Tony) Yuan
Cheminformatics Specialist, Novartis
Institute of BioMedical Research,
Cambridge, MA

Philip Zhang, Ph. D.
Special Counsel, Colley Godward
Kronish LLP, Boston, MA

Weiyi(Wendy) Zhang, Ph. D.
Senior Director, Business
Development, Sundia MediTech,
Shanghai, China

Liping Zhou, Ph. D.
Investigator, Novartis Institute of
BioMedical Research, Cambridge, MA

Zhendong Zhu, Ph. D.
Principal Scientist, Avila Therapeutics,
Inc, Waltham, MA

Founding President

Jun Han, Ph. D.
Global R&D Project Manager, Teva
Pharmaceuticals, Inc., Pomona, NY

Immediate Past-President

Junjun Wu, Ph. D.
Principal Research Scientist, Wyeth
Research, Cambridge, MA

CABA Legal Counsel

Fred Gilman
Attorney at Law, Lynch, DeSimone &
Nylen, LLP, Boston, MA

CABA Advisors

Tomi Sawyer, Ph. D.
Chief Scientific Officer and Senior
Vice-President, Aileron Therapeutics,
Cambridge, MA

Yibin Xiang, Ph. D.
Senior Director/Medicinal Chemistry,
Genzyme Corporation, Cambridge,
MA

Steve Tam, Ph. D.
Senior Director/Chemistry, Wyeth
Research, Cambridge, MA

Gangfeng Xu, Ph. D.
VP/Head of Asia & Pacific Business
Development, Wyeth Research, NY

Jianling Wang, Ph. D.
Section Manager, Novartis Institute of
BioMedical Research, Cambridge, MA

Howard Yuwen, Ph. D.
Sr. Director, Shire Pharmaceuticals,
Cambridge, MA

Wei Zhang, Ph. D.
Director, Market Research, Altus
Pharmaceuticals Inc., Cambridge, MA

Chen Li, Ph. D.
Head of Research and Chief Scientific
Officer, Roche R&D Center(China)
Ltd.

Steve Yang, Ph. D.
Vice President and Head of Pfizer Asia
R&D(Shanghai), Shanghai, China

Tim Clackson, Ph. D.
Sr. VP and Chief Scientific Officer,
Ariad Pharmaceuticals Inc., Cambridge,
MA

Youssef Bennani, Ph. D.
Vice President/Discovery Chemistry,
Vertex Pharmaceuticals Inc.,
Cambridge, MA

Dawei Ma , Ph. D.
Professor, Shanghai Institute of
Organic Chemistry, Shanghai, China

Roger Tung, Ph. D.
CEO and President, Concert
Pharmaceuticals, Lexington, MA

Steve Projan, Ph. D.
Vice President, Global Head of
Infectious Diseases, Novartis Institute
of BioMedical Research, Cambridge,
MA

John Piwinski, Ph. D.
Group VP and Site Head, Schering-
Plough Research Institute, Cambridge,
MA

Tarek Mansour, Ph. D.
VP and Head of Chemical Sciences,
Wyeth Research Institute, Wyeth
Pharmaceuticals

Liming Shao, Ph. D.
Senior Director/Medicinal Chemistry,
Sepracor Inc., Marlborough, MA

Pierre Frederic Dodion
Senior Vice President and Chief
Medical Officer
ARIAD Pharmaceuticals, Cambridge,
MA



CABA 2008 Technology and Investment symposium was held at MIT Faculty Club.



CABA's founding leaders: (from left to right) Dr. Zhao-Kui Wan, Dr. Jun Han, Dr. Junjun Wu, Dr. Yihan Wang and Dr. Liping Zhou



CABA, ACMA, CAIPLA and OCEAN co-hosted the 2008 Chinese New Year Gala.



Dr. Yanhua Liu, the vice minister of MOST of China, met members and friends of CABA at Harvard in Dec 2008.

Sponsor Updates

2008-2009 CABA Events Top Sponsors



Howfond

In China, Custom Drug Discovery: Low Cost, High Quality!

Wuxi Howfond Biopharma Co., Ltd. (无锡好芳德药业有限公司) located in Wuxi, China, is a research-driven and customer-focused company. With 150,000 sq ft modern R&D and manufacturing facilities, Wuxi Howfond offers global pharmaceutical and biotech companies a broad portfolio of custom services for drug discovery, development and production.

Services On Chemistry

FTE Contract Research: Discovery chemistry to lead optimization / hit and lead follow-up, and focused library synthesis / process development

Custom Synthesis: Building blocks / library templates / libraries / intermediates / literature and commercial reference compounds

Scale-up Synthesis: Intermediates to APIs / milligrams to tons quantity

Services On Pharmacokinetics/Pharmacology

ADMET Studies
Protocol Design
Formulation Development
In-life Study
Sample And Data Analysis
Report Preparation
Animal Models

Synthetic Experiences

Heterocyclic Compounds
Pyrimidines, Pyrazoles, Pyrroles,
Pyridines, Oxazoles, Quinolines,
Indoles, Triazole and Tetrazoles
Arylboronic Acids
Unnatural Amino Acids

Expertise On Chiral Synthesis

Asymmetrical Catalysis
Resolution of Enantiomers
Total Synthesis of Natural Products

South Bldg, 1608 Huishan Blvd, Huishan District, Wuxi, China 214174 Tel: +86-510-8359-1618 x 8011 Fax: +86-510-8359-1616
<sales@howfond.cn> <www.howfond.com>

**Q Labtech**

Weimin Qian, a former senior scientist at Pfizer Global Research & Development, invented this unique lab device, Q-Tube. Weimin combines the best of a microwave synthesizer (short reaction time), a pressure tube (for volatile reagents) and a round bottom flask (scalability) into a single and simple device.

Q-Tube could:

- Replace a Parr Shaker and a hydrogen generator
- Replace a CO generator
- Replace a Schlenk reaction vessel
- Be used for parallel / library synthesis, optimization (faster than microwave's sequential run)

Contact info:

Q Labtech LLC
36 Hickory Lane
Waterford, CT 06385
USA
860-884-6507
888-361-5328 (fax)
WWW.QLABTECH.COM

For more information, please visit www.QLABTECH.com



Luknova® Inc. is a leading supplier of flash chromatography consumables and their accessories. We design, manufacture, and distribute high-performance packed flash columns, solid load columns, solid phase extraction (SPE) columns, column adaptors, and high purity silica gel for organic compound separation and purification. Luknova developed high quality flash columns using our proprietary design and our undisclosed unique packing technology. We have management and operation facilities in New Jersey and Massachusetts.

Our products have been distributed worldwide, including North America, Europe, and Asia. Our customers come from pharmaceutical industry, biotechnology, and chemical research companies and laboratories. Luknova provides customers not only innovative products but also cost-effective solutions.



www.luknova.com



Customers' Success is Sundia's Success!



- Top CRO in China
- Integrated R&D Services for Drug Discovery and Pharmaceutical Development
- Deloitte Technology Fast Top 50 Award in 2008 in China,
- Venture Top 50 Award in 2007 and 2008 by Zero2IPO

Upcoming Events

New England Chinese Professional's Summer Outing

Organized by CABA , ACMA, CAIPLA & OCEAN

Saturday, August 8th, 2009

Time: 10:00 AM - 4:00 PM

Location: Hopkinton State Park, Hopkinton, Massachusetts

Website: www.cabaweb.org

2009 CABA Technology, Investment and Entrepreneurship Symposium - Entrepreneurship in Biotechnology *organized by CABA*

Saturday, November 14th, 2009

Time: 12:00 PM - 9:30 PM

Location: Doubletree Guest Suites, 400 Soldiers Field Road, Boston

Website: www.cabaweb.org

Teen Entrepreneurship 101: Youth Summer Camp *organized by OCEAN*

Session I: July 27th ~ July 31st Session II: August 24th ~ August 28th, 2009

Time: 9:00 AM – 4:30 PM

Location: MIT campus

Website: www.ocean-usa.org/oec

World Pharmaceutical Summit 2009, *Co-hosted by CABA*

September 16th ~ September 18th, 2009.

Location: InterContinental Shanghai Pudong, China

Website: www.cfeci.com

The 7th International Pharmaceutical High Technology Summit

第7 届中国国际新药创制前沿技术与产业化发展高峰论坛暨项目合作洽谈会

September 22nd ~ September 25th, 2009

Location: 重庆欧瑞锦江大酒店

Website: www.pharmtec.org.cn

Wuhan Hua-Chuang-Hui (华创会)

Thursday, October 15 ~ Saturday, October 17, 2009

Location: 武汉新世界大酒店, 武汉科技会展中心

Website: www.hch.org.cn

Reach thousands of professionals, executives and scientific researchers in biomedical industries throughout the world!

Advertise in CABA CONNECT

Contact our advertisement editor at cabaconnect@gmail.com

Deadlines:

October 31, 2009 for winter '09 issue.

February 6, 2009 for Spring '10 issue.

CABA members, send your comments, suggestions and thoughts to us; Contribute to "Member Spotlights" column by sending us a brief summary of your recent achievements on academics or/and careers.

Volunteer coordinator needed for news reporting, editing and photography. Contact us at cabaconnect@gmail.com if you are interested.



Chinese-American Biomedical Association

P. O. Box 600241

Newtonville, MA 02460 USA

www.cabaweb.org

Non-profit Org.
US postage paid
Newton, MA 02460